3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Interventions
Specimen Handling
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Counseling
2
Bupropion
2
vactosertib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine phosphate
1
erdafitinib
1
entinostat
1
defactinib
1
dabrafenib
1
copanlisib
1
capmatinib
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
capmatinib
×
Other hematologic neoplasm
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled